Melissa R Junttila
机构: ORIC Pharmaceuticals
每年引用次数
引用次数
引用: 11,503
H-指数: 38
I10-指数 : 46
出版物: 109
p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells
M R Junttila , R Ala-aho , T Jokilehto , J Peltonen
Oncogene 26 ( 36) 5267 -5279
168
2007
Mechanisms of MYC stabilization in human malignancies
Melissa R JUNTTILA , Jukka WESTERMARCK
Cell cycle 8 ( 3) 507 -507
2009
Onkoproteiini CIP2A kertoo mahasyövän ennusteesta: [ in press/J Natl Cancer Inst]
Jukka Westermarck , Annabrita Hemmes , Ari Ristimäki , Camilla Böckelman
Duodecim 125 1434 -1435
2009
Translational value of mouse models in oncology drug development
Stephen E Gould , Melissa R Junttila , Frederic J de Sauvage
Nature Medicine 21 ( 5) 431 -439
164
2015
Abstract S1-07: HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer
Teemu T Junttila , Ji Li , Jennifer Johnston , Maria Hristopoulos
Cancer Research 75
1
2015
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Anneleen Daemen , Jonathan Cooper , Szymon Myrta , Matthew J Wongchenko
Clinical Cancer Research 27 ( 4) 1162 -1173
1
2021
ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma
Melissa R Junttila , Arghya Ray , Robert Warne , Xi Chen
Cancer Research 82 ( 12\_Supplement) 2074 -2074
2022
Harnessing the predictive power of preclinical models for oncology drug development
Alexander Honkala , Sanjay V Malhotra , Shivaani Kummar , Melissa R Junttila
Nature Reviews Drug Discovery 21 ( 2) 99 -114
29
2022
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan , Jason Liang , Ivana Yen , Frances Shanahan
Cell reports 38 ( 6)
23
2022
EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation
Ariel Pribluda , Anneleen Daemen , Anthony Nelson Lima , Xi Wang
Elife 11 e57648 -e57648
3
2022
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models
Anneleen Daemen , Jessica D Sun , Aleksandr Pankov , Frank L Duong
Cancer Research 81 ( 13)
3
2021
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida , Andrew W Hahn , Neal Shore , Neeraj Agarwal
Clinical Cancer Research OF1 -OF10
1
2024
Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner
Marc Hafner , Nicholas Dompe , Wei Zhou , Eva Lin
Cancer Research 79 ( 13_Supplement) 4410 -4410
1
2019
Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer
Matthew A Marx , Aaron C Burns , Nidhi Arora , Thomas P Bobinski
Cancer Research 84 ( 7_Supplement) ND04 -ND04
2024
ORIC-613, a potential first-and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models
Kyle A Edgar , Siobhan McRee , Gina Andretta , Chelsea Chen
Cancer Research 84 ( 6_Supplement) 594 -594
2024
ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models
Anneleen Daemen , Natalie Yuen , Amber Wang , Aleksandr Pankov
Cancer Research 84 ( 6_Supplement) 6586 -6586
2024
A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer
M Dorso , Payal T Patel , Aleksandr Pankov , Jacob A Boyer
Cancer Research Communications 3 ( 9) 1788 -1799
2023
Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer
Anneleen Daemen , Natalie Yuen , Aleksandr Pankov , Eric A Ariazi
Cancer Research 83 ( 7_Supplement) 2791 -2791
2023
Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts
Kyle A Edgar , Amy Young , Jared Moore , Xi Chen
Cancer Research 82 ( 12)
2022
ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models
Jessica D Sun , Haiying Zhou , Wayne Kong , Natalie Yuen
Cancer Research 80 ( 16)
2020